Interviewer: Professor Parmar,
thank you for taking the time today to do
this interview on the use of
remdesivir as a COVID-19 therapy.
Can you give us an overview of this drug?
Prof. Parmar: Remdesivir is a drug
that's been around for a while,
it was originally used to treat Ebola and
other virus infections such as SARS.
It wasn't very successful
in treating at Ebola,
there were more effective drugs, but
it was noticed that it was effective or
active against coronaviruses,
including SARS for example.
Remdesivir was seen to be active in
the laboratory against other
coronaviruses such as SARS and
when tested against COVID-19
it was also seen to be active,
so it seemed to be a natural
step to test it in patients
especially as the safety and
dosing had been worked out for
treating patients with Ebola.
Interviewer: Could you give an overview
on the clinical trial that is under way
for this drug?
Prof. Parmar: Yes,
this trial started in February of 2020.
We started recruiting subjects to
this trial at the end of March and
the last patient was
randomized on 19th April.
This was a multinational clinical trial
funded by the National Institutes of
Health (NIH) in the US, about 75 hospitals
globally took part in the trial and